These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7593733)

  • 1. Health-related quality of life in patients with major depression who are treated with moclobemide.
    Walker V; Streiner DL; Novosel S; Rocchi A; Levine MA; Dean DM
    J Clin Psychopharmacol; 1995 Aug; 15(4 Suppl 2):60S-67S. PubMed ID: 7593733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moclobemide twice daily in the treatment of major depressive episode: a double-blind, multicenter comparison with different three-times-daily dosage schedules.
    Gagiano CA; Hart GA; Bodemer W; Schall R
    Clin Neuropharmacol; 1994; 17 Suppl 1():S1-8. PubMed ID: 7954480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moclobemide in continuation treatment of major depressive episodes: an open follow-up study over six months.
    Gagiano CA; Müller FG; de Kock RF; Schall R
    J Clin Psychopharmacol; 1995 Aug; 15(4 Suppl 2):46S-50S. PubMed ID: 7593731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The SF-36 instrument for the follow-up of health-related quality-of-life assessment of patients undergoing home parenteral nutrition for benign disease.
    Pironi L; Paganelli F; Mosconi P; Morselli-Labate AM; Spinucci G; Merli C; Guidetti M; Miglioli M
    Transplant Proc; 2004 Mar; 36(2):255-8. PubMed ID: 15050126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the efficacy and tolerability of moclobemide given as a single daily dose or in three divided doses per day for the treatment of patients with a major depressive episode (DSM-III-R).
    Newburn G; Edwards R; Thomas H; Collier J; Fox K; Collins C; Cramer D; Reeves J; Caracatsanis A
    J Clin Psychopharmacol; 1995 Aug; 15(4 Suppl 2):10S-15S. PubMed ID: 7593724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moclobemide twice daily in the treatment of major depressive episode: a double-blind, multicenter comparison with different three times daily dosage schedules.
    Gagiano CA; Müller FG; Berk M; Joubert PM; Brown RG; Schall R
    J Clin Psychopharmacol; 1995 Aug; 15(4 Suppl 2):4S-9S. PubMed ID: 7593729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-related quality of life of patients with cystic fibrosis assessed by the SF-36 questionnaire.
    Uchmanowicz I; Jankowska-Polańska B; Wleklik M; Rosinczuk-Tonderys J; Dębska G
    Pneumonol Alergol Pol; 2014; 82(1):10-7. PubMed ID: 24391066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moclobemide versus fluoxetine in the treatment of major depressive disorder in adults.
    Lapierre YD; Joffe R; McKenna K; Bland R; Kennedy S; Ingram P; Reesal R; Rickhi BG; Beauclair L; Chouinard G; Annable L
    J Psychiatry Neurosci; 1997 Mar; 22(2):118-26. PubMed ID: 9074306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary experience with moclobemide for the treatment of depressive disorders in Malaysia.
    Indran SK
    Singapore Med J; 1995 Apr; 36(2):189-90. PubMed ID: 7676265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Association between health related quality of life and severity of depression in patients with major depressive disorder].
    Cao Y; Li W; Shen J; Zhang Y
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Feb; 36(2):143-8. PubMed ID: 21368424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moclobemide and fluoxetine in the prevention of relapses following acute treatment of depression.
    Lonnqvist J; Sihvo S; Syvälahti E; Sintonen H; Kiviruusu O; Pitkanen H
    Acta Psychiatr Scand; 1995 Mar; 91(3):189-94. PubMed ID: 7625194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Health-related quality of life assessment in depression after low-frequency transcranial magnetic stimulation].
    Dumas R; Boyer L; Richieri R; Guedj E; Auquier P; Lançon C
    Encephale; 2014 Feb; 40(1):74-80. PubMed ID: 24091070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of sleep questionnaires in assessing the effect of moclobemide on the sleep profiles of depressive patients.
    Campos JA; Deitos TF; Lima MC; Salomão K; Salomão S; Souza AC
    Clin Neuropharmacol; 1994; 17 Suppl 1():S19-28. PubMed ID: 7954481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moclobemide and sertraline in the treatment of depressive disorders: a comparative study.
    Orsel Donbak S; Turkçapar MH; Ozturk Kiliç EZ; Demirergi N; Akdemir A; Sirin A; Ozbay MH
    Acta Psychiatr Belg; 1995; 95(3):139-51. PubMed ID: 8525856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moclobemide for depression: an Australian psychiatric practice study.
    Tiller JW; Johnson GF; Burrows GD
    J Clin Psychopharmacol; 1995 Aug; 15(4 Suppl 2):31S-34S. PubMed ID: 7593727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching to moclobemide to reverse fluoxetine-induced sexual dysfunction in patients with depression.
    Ramasubbu R
    J Psychiatry Neurosci; 1999 Jan; 24(1):45-50. PubMed ID: 9987207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of health-related quality of life in dialysis patients. Personal experience using questionnaire SF-36].
    Kusztal M; Nowak K; Magott-Procelewska M; Weyde W; Penar J
    Pol Merkur Lekarski; 2003 Feb; 14(80):113-7. PubMed ID: 12728668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of moclobemide on cognitive functions of nine depressed patients: pilot trial with neurophysiological and neuropsychological indices.
    Galderisi S; Mucci A; Bucci P; Mignone ML; Maj M
    Neuropsychobiology; 1996; 33(1):48-54. PubMed ID: 8821375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of depression using MAO-A inhibitors: an open study of a direct switch from moclobemide to tri-/tetracyclic antidepressants].
    Becker T; Struck M; Laux G
    Psychiatr Prax; 1989 Aug; 16 Suppl 1():44-7. PubMed ID: 2685856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder.
    Suthoff E; Kosinski M; Arnaud A; Hodgkins P; Gunduz-Bruce H; Lasser R; Silber C; Sankoh AJ; Li H; Werneburg B; Jonas J; Doherty J; Kanes SJ; Bonthapally V
    J Affect Disord; 2022 Jul; 308():19-26. PubMed ID: 35378149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.